Disease · MP_0001914
Comparisons in its trials86
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 86
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Prehospital Tranexamic Acid vs Control: deaths from any cause | 36 of 447 | 45 of 456 | 903 | NCT02086500 | Trial comparisons |
| Prehospital Tranexamic Acid vs Control: serious adverse events | 4 of 447 | 7 of 456 | 903 | NCT02086500 | Trial comparisons |
| Prehospital Tranexamic Acid vs Control: Multiple Organ Failure | 33 of 447 | 39 of 453 | 900 | NCT02086500 | Trial comparisons |
| Prehospital Tranexamic Acid vs Control: 24 Hour Mortality | 16 of 447 | 17 of 453 | 900 | NCT02086500 | Trial comparisons |
| Prehospital Tranexamic Acid vs Control: Hyperfinbrinolysis | 145 of 447 | 144 of 453 | 900 | NCT02086500 | Trial comparisons |
| Prehospital Tranexamic Acid vs Control: Acute Lung Injury | 42 of 447 | 39 of 453 | 900 | NCT02086500 | Trial comparisons |
| Prehospital Tranexamic Acid vs Control: Nosocomial Infection | 88 of 447 | 66 of 453 | 900 | NCT02086500 | Trial comparisons |
| Prehospital Tranexamic Acid vs Control: 30 Day Mortality | 36 of 442 | 45 of 452 | 894 | NCT02086500 | Trial comparisons |
| IV TXA Group vs Topical TXA Group: The Number Patients Requiring a Transfusion | 2 of 320 | 6 of 320 | 640 | NCT01940523 | Trial comparisons |
| Topical Tranexamic Acid vs Intravenous Tranexamic Acid: serious adverse events | 0 of 320 | 0 of 320 | 640 | NCT01940523 | Trial comparisons |
| Alteplase vs Saline Placebo: serious adverse events | 114 of 249 | 151 of 251 | 500 | NCT00784134 | Trial comparisons |
| Octaplex vs Frozen Plasma: Comparison of the Incidence of Death Between Octaplex and FP Groups | 7 of 213 | 8 of 207 | 420 | NCT05523297 | Trial comparisons |
| Octaplex vs Frozen Plasma: Comparison of Incidence of Serious Treatment-emergent Adverse Events Between Octaplex and FP Groups | 77 of 213 | 98 of 207 | 420 | NCT05523297 | Trial comparisons |
| Octaplex vs Frozen Plasma: deaths from any cause | 7 of 213 | 8 of 207 | 420 | NCT05523297 | Trial comparisons |
| Octaplex vs Frozen Plasma: serious adverse events | 77 of 213 | 98 of 207 | 420 | NCT05523297 | Trial comparisons |
| Relugolix Plus E2/NETA (Group A) vs Placebo (Group C): Sustained Amenorrhea Rate (No Or Negligible Bleeding) | 67 of 128 | 7 of 127 | 255 | NCT03049735 | Trial comparisons |
| Relugolix Plus E2/NETA (Group A) vs Placebo (Group C): Number Of Responders With At Least 20 Points Decrease In UFS-QoL Bleeding And Pelvic Discomfort Scale Score | 79 of 128 | 35 of 127 | 255 | NCT03049735 | Trial comparisons |
| Relugolix Plus E2/NETA (Group A) vs Placebo (Group C): Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score | 78 of 128 | 45 of 127 | 255 | NCT03049735 | Trial comparisons |
| Relugolix Plus E2/NETA (Group A) vs Placebo (Group C): Sustained Amenorrhea Rate (No Or Negligible Bleeding) | 63 of 125 | 4 of 129 | 254 | NCT03103087 | Trial comparisons |
| Relugolix Plus E2/NETA (Group A) vs Placebo (Group C): Number Of Responders With At Least 20 Points Decrease in UFS-QoL Bleeding And Pelvic Discomfort Scale Score | 79 of 125 | 37 of 129 | 254 | NCT03103087 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MP_0001914/comparisons